Patents by Inventor Peter Ettmayer

Peter Ettmayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • B-RAF kinase inhibitors
    Patent number: 9290507
    Abstract: The present invention encompasses compounds of general formula (1) where in the groups R0 to R3 and L are defined as in claim 1, which are suitable for the 5 treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: March 22, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Steurer, Peter Ettmayer, Andreas Mantoulidis
  • Chemical compounds
    Patent number: 8889665
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: November 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Steffen Steurer, Irene Waizenegger
  • Pyridyltriazoles
    Patent number: 8865703
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R0 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: October 21, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Ettmayer, Steffen Steurer
  • Substituted heteroaryl inhibitors of B-RAF
    Patent number: 8778929
    Abstract: The present invention relates to new compounds of general formula (I), wherein the groups R1 to R3, X1, X2, X3 and L1 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof in such a treatment.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: July 15, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Steurer, Peter Ettmayer, Andreas Mantoulidis
  • Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors
    Patent number: 8653087
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, X1, X2, X3, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof in such a treatment.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: February 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Mantoulidis, Georg Dahmann, Peter Ettmayer, Christian Klein, Steffen Steurer, Irene Waizenegger, Stephan Karl Zahn
  • Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
    Patent number: 8569316
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R4, X1, X2, X3, X4, X5, Q, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: October 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Ettmayer, Andreas Mantoulidis
  • PYRIDYLTRIAZOLES
    Publication number: 20130225562
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R0 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
    Type: Application
    Filed: March 25, 2011
    Publication date: August 29, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter Ettmayer, Steffen Steurer
  • B-RAF KINASE INHIBITORS
    Publication number: 20130190286
    Abstract: The present invention encompasses compounds of general formula (1) where in the groups R0to R3 and L are defined as in claim 1, which are suitable for the 5 treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.
    Type: Application
    Filed: March 25, 2011
    Publication date: July 25, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Steffen Steurer, Peter Ettmayer, Andreas Mantoulidis
  • PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20130023531
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.
    Type: Application
    Filed: January 19, 2012
    Publication date: January 24, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andreas MANTOULIDIS, Peter ETTMAYER
  • Chemical compounds
    Patent number: 8203001
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, M1, L1 and Q are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: June 19, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ulrich Reiser, Peter Ettmayer, Oliver Kraemer, Peter Sennhenn, Walter Spevak
  • Chemical compounds
    Patent number: 8198308
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: June 12, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Steurer, Peter Ettmayer, Andreas Mantoulidis, Ioannis Sapountzis, Martin Steegmaier
  • PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS
    Publication number: 20120094975
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, X1, X1, X3, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell pro-liferation, and the use thereof in such a treatment.
    Type: Application
    Filed: September 8, 2009
    Publication date: April 19, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andreas Mantoulidis, Georg Dahmann, Peter Ettmayer, Christian Klein, Steffen Steurer, Irene Waizenegger, Stephan Karl Zahn
  • PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES
    Publication number: 20120046270
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R4, X1, X2, X3, X4, X5, Q, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.
    Type: Application
    Filed: February 17, 2010
    Publication date: February 23, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter Ettmayer, Andreas Mantoulidis, Steffen Steurer
  • NEW CHEMICAL COMPOUNDS
    Publication number: 20110312939
    Abstract: The present invention relates to new compounds of general formula (I), wherein the groups R1 to R3, X1, X2, X3 and L1 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof in such a treatment.
    Type: Application
    Filed: September 28, 2009
    Publication date: December 22, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Steffen Steurer, Peter Ettmayer, Andreas Mantoulidis
  • NEW CHEMICAL COMPOUNDS
    Publication number: 20110183952
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: July 1, 2008
    Publication date: July 28, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Steffen Steurer, Irene Waizenegger
  • NEW CHEMICAL COMPOUNDS
    Publication number: 20110059938
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: November 15, 2010
    Publication date: March 10, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Steffen STEURER, Peter ETTMAYER, Andreas MANTOULIDIS, Ioannis SAPOUNTZIS, Martin STEEGMAIER
  • Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
    Patent number: 7825260
    Abstract: Compounds of formula I, wherein X, a, b, R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: November 2, 2010
    Assignee: Novartis AG
    Inventors: Rainer Albert, Claus Ehrhardt, Peter Ettmayer, Klaus Hinterding, Klemens Högenauer, Peter Nussbaumer
  • CHEMICAL COMPOUNDS
    Publication number: 20100240657
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition with the above-mentioned properties.
    Type: Application
    Filed: July 1, 2008
    Publication date: September 23, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Martin Steegmaier, Steffen Steurer, Irene Waizenegger
  • Phenylpyrimidine amines as IgE inhibitors
    Patent number: 7759357
    Abstract: An amine, which is substituted by phenyl-substituted pyrimidin; and phenyl; and a third substituent and its use as an immunoglobulin E (IgE) inhibitor.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: July 20, 2010
    Assignee: Novartis AG
    Inventors: Murty Bulusu, Peter Ettmayer, Klaus Weigand, Max Woisetschlager
  • CHEMICAL COMPOUNDS
    Publication number: 20090258857
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, M1, L1 and Q are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.
    Type: Application
    Filed: June 13, 2007
    Publication date: October 15, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ulrich Reiser, Peter Ettmayer, Oliver Kraemer, Peter Sennhenn, Walter Spevak